Kyongbo Pharmaceutical Co., Ltd. (214390) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Kyongbo Pharmaceutical Co., Ltd. (214390:KRX), powered by AI.

Current Price
₩5,580
P/E Ratio
731.8
Market Cap
133.4B
Sector
Healthcare
What is the Kyongbo Pharmaceutical Co., Ltd. stock price forecast?

Kyongbo Pharmaceutical Co., Ltd. is currently trading at ₩5,580. View real-time AI analysis on Alpha Lenz.

What is Kyongbo Pharmaceutical Co., Ltd. insider trading activity?

View the latest insider trading data for Kyongbo Pharmaceutical Co., Ltd. on Alpha Lenz.

What is Kyongbo Pharmaceutical Co., Ltd.'s P/E ratio?

Kyongbo Pharmaceutical Co., Ltd.'s P/E ratio is 731.8.

Kyongbo Pharmaceutical Co., Ltd.

KRX · 214390
₩5,580+90(+1.64%)Market closedKRX regular session 09:00–15:30 KST
Ask about Kyongbo Pharmaceutical Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Kyongbo Pharmaceutical Co., Ltd. trades at a P/E of 731.8 (premium valuation) with modest ROE of 0.1%. 3Y revenue CAGR of 10.4% highlights clear growth momentum.

Ask for details

Company Overview

Kyongbo Pharmaceutical Co., Ltd. is a prominent pharmaceutical company engaged in the research, development, and manufacture of medical products. Its primary function is to create and supply a wide range of pharmaceutical solutions, aiming to enhance human health and well-being. The company specializes in producing a variety of medications, including antibiotics, cardiovascular drugs, and gastroenterological products, reflecting its commitment to addressing diverse medical needs. Kyongbo Pharmaceutical Co., Ltd. plays a significant role in the healthcare sector, impacting both domestic and international markets with its high-quality pharmaceutical offerings. Founded with a mission to improve healthcare outcomes, it continuously invests in innovation and clinical research to ensure the efficacy and safety of its products. As a key player in the pharmaceutical industry, Kyongbo Pharmaceutical Co., Ltd. contributes to the availability of essential medicines, supporting the global healthcare infrastructure and helping meet the rising demand for effective health solutions.

CEO김태영
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
0

Company Statistics

FY 2025

Profile

₩133,400,278,800Market Cap
₩264,104,056,810Revenue
23.91MShares Out
0Employees

Margins

38.74%Gross
6.88%EBITDA
1.33%Operating
0.17%Pre-Tax
0.07%Net

Valuation

731.79P/E
0.92P/B
0.51EV/Sales
13.91EV/EBITDA
-3.91P/FCF

Growth (CAGR)

10.40%Rev 3Yr
4.17%Rev 5Yr
36.20%Op Inc 3Yr
-16.49%Op Inc 5Yr
-33.16%Net Inc 3Yr
-54.55%Net Inc 5Yr

Returns

0.06%ROA
0.12%ROE
1.57%ROIC

Financial Health

₩7,228,428,310Cash & Cash Equivalents
₩166,571,737,380Net Debt
119.26%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Kyongbo Pharmaceutical Co., Ltd. (ticker: 214390) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $133.4B.

The current price is ₩5,580 with a P/E ratio of 731.79x and P/B of 0.92x.

ROE is 0.12% and operating margin is 1.33%. Annual revenue is $264.1B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Kyongbo Pharmaceutical Co., Ltd. (214390) Stock Forecast 2026 ₩5,580 — Price, Financials & Analyst Targets | Alpha Lenz